Orphan Drug Act Reform: Will the Loophole be Closed During the Biden Administration?

Published date29 January 2021
Subject MatterFDA,Prescription Drugs,Orphan Drugs,Pharmaceutical Industry,Biden Administration
AuthorAkkad Moussa,April Abele Isaacson,Kimberlynn Davis Ph.D.
Law FirmKilpatrick Townsend & Stockton LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT